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Introduction
In recent years, new-generation antiepileptic drugs have
found a place among classic headache prophylaxis drugs
prescribed by the guidelines of the International Headache
Society, such as beta-blockers, calcium antagonists and
tricyclic antidepressants.
The question is whether, thanks to their tolerability
and rapid onset of action, these drugs should be consid-
ered as first-choice prophylaxis medication rather than
simply as alternative drugs.
The hypothesis that cortical hyperexcitability may
play an important role in the physiopathology of
migraine has led to the therapeutic use of antiepileptic
drugs [1–3].
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Abstract The hypothesis that corti-
cal hyperexcitability may play an
important role in the physiopatholo-
gy of migraine has lead to the thera-
peutic use of antiepileptic drugs in
headache prophylaxis. Cortical
hyperexcitability is due to an imbal-
ance between neuronal inhibition,
mediated by gamma-aminobutyrric
acid (GABA), and neuronal excite-
ment, mediated by excitatory
aminoacids. It becomes therefore
clear how cortical excitability may
be modulated by acting on mecha-
nisms such as the synthesis and
metabolism of GABA and on targets
such as GABA and glutamate recep-
tors and on sodium and calcium
channels. The question is, whether,
thanks to their tolerability and rapidi-
ty of action, these should be consid-
ered as first-choice prophylaxis
drugs rather than simply as alterna-
tive drugs. Thanks to their action on
the key-mechanisms implicated in
the genesis and maintenance of pain,
valproic acid, gabapentin, topira-
mate, levetiracetam and lamotrigine
have all the requisites in terms of
efficacy, tolerability and rapidity of
action that are requested from a drug
in order to be considered a first-
choice drug rather than simply an
alternative to the drugs currently
used. The expansion, however, of
medical areas in which antiepileptic
drugs are prescribed and the growing
number of patients using them,
require an increased sensitivization
in order to avoid their incorrect use.
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Cortical hyperexcitability is caused by an imbalance
between neuronal inhibition, mediated by gamma-
aminobutyric acid (GABA), and neuronal excitement,
mediated by excitatory amino acids.
It therefore becomes clear how cortical excitability
may be modulated by acting on mechanisms such as the
synthesis and metabolism of GABA and on targets such as
GABA and glutamate receptors as well as on sodium and
calcium channels.
An abnormal neuronal excitability may trigger a depo-
larization, considered to be responsible for the ‘spreading
depression’ [1] and for the abnormal entry of calcium that
can cause a mitochondrial accumulation of calcium.
Thus, ion channels seem to play a very specific role. In
particular voltage-dependant ion channels, are important
for neuronal function because they modulate neuronal
excitability [4]. The interaction between regulatory pro-
teins, neurotransmitters such as serotonin, and other
receptors plays a role in the constant regulation of the P/Q
calcium channel function.
Ion channels, in particular the L sub-group of voltage-
dependant channels, are important for the genesis of cal-
cium-mediated action potentials. Their function includes
the control and maintenance of the electric potentials
across cell membranes, signal transductions and the regu-
lation of action potentials in the dendrites as they permit
the entry of calcium in the cell and, thus, the release of
neurotransmitters [5].
The modes of action of antiepileptic drugs in headache
can be summarized as functioning via two mechanisms. A
given antiepileptic drug may act by only one or by both
mechanisms:
– The suppression of neuronal hyperexcitability that, in
turn, inhibits spreading depression.
– The modification of the dysfunction of voltage-depen-
dant ion channels (consisting in the alteration of the
inactivation gating system of sodium, potassium and
calcium channels that generates an instability in neu-
ronal excitability).
We can therefore identify some ‘key targets’ on which
antiepileptic drugs may act determining a positive effect
in the control of a headache attack:
a. The possibility of modulating excitatory pathways
mediated by glutamate receptors.
b. The possibility of inhibiting repeated firing of struc-
tures implicated in the processing of head pain (kin-
dling phenomenon).
Which antiepileptic drugs are currently used and what is
their mode of action?
During the past 7 years, nearly all drugs used for epilepsy
have been experimented on using different scientific
methods, often only in ‘open-label’ studies.
The only antiepileptic drugs that have proven to be
truly efficacious in the prophylactic treatment of primary
headaches are: valproic acid, gabapentin, topiramate, lev-
etiracetam and lamotrigine. The efficacy of these drugs
has been proven, but with varying clinical validity, as
shown in Table 1.
If we closely inspect the modes of action of single
antiepileptic drugs, we can delineate their neuroprotective
effect and, for some of them, their adjunctive properties,
considering the rational basis for their use and their key
targets.
Modes of action of antiepileptic drugs in headache and
their neuroprotective effect
Valproic acid [5, 7–10]
1. Inhibition of GABA-aminotransferase, enzyme impli-
cated in the degradation of GABA.
2. Increased synthesis of GABA, through the modulation
of the glutamic-acid decarboxylase, and decrease in
glutamate concentrations.
3. Suppression of the depolarization mediated by the
activation of NMDA-glutamate receptors.
4. Activation of GABA receptors in the dorsal raphe
nucleus and subsequent reduced firing from serotonin-
ergic neurons.
5. Inactivation of voltage-dependant sodium channels.
6. Inhibition of GABA re-uptake.
7. Blockage of T calcium channels.
Table 1 Efficacy of antiepileptic drugs in the treatment of primary headaches
Evidence level Scientific validity Clinical validity Clinical features of headache
Gabapentin A ++ ++ Migraine without aura
Sodium valproate A +++ ++ Migraine with aura
Topiramate B ++ ++ Migraine with and without aura
Lamotrigine B ++ ++ SUNCT syndrome
Levetiracetam B + + Migraine without aura
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Furthermore, the following mechanisms of action have
been discovered:
– Modulation of trigeminal nociceptive neurons in the
meninges.
– Blockage of sterile neurogenic inflammation, through
a GABAA receptor-mediated mechanism, with a
reduction of substance P and plasma protein dural
extravasation.
Gabapentin [5, 11, 12]
1. Reduction of neuronal hyperexcitability through the
increase of GABA synthesis and its non-vesicular
release.
2. Modulation of voltage-dependant ion channel dysfunc-
tion through a high-affinity binding to the α2δ volt-
age-dependant calcium channel site which regulates
the increase of the calcium ion flux.
3. Reduction of glutamate concentration through the
inhibition of aminotransferase and the stimulation of
glutamic dehydrogenase.
4. Increase of serum serotonin levels.
Topiramate [5, 13, 14]
1. Reduction of neuronal hyperexcitability through a
GABAergic potentiation mediated by GABA-depen-
dant chlorine flux.
2. Modulation of the voltage-dependant ion channel dys-
function through the blockage of sodium and calcium
voltage-dependant ion channels.
3. Antagonism of AMPA/kainate-type glutamate recep-
tors.
Lamotrigine [15]
1. Blockage of sodium voltage-dependant ion channels.
2. Stabilization of neuronal membranes through the inhi-
bition of the release of glutamate.
Levetiracetam [16, 17]
1. Inhibition of L and N calcium voltage-dependant ion
channels.
2. Action on perimeningeal vasodilation and on neuro-
genic inflammation.
The dosage of antiepileptic drugs in the treatment of
headache is around 50% of the dose used in epilepsy,
since clinical evaluations have demonstrated that there is
no correlation between increasing dosages and clinical
efficacy.
The mean dosage of each antiepileptic drug is the fol-
lowing: valproic acid, 600–1,200 mg/day; gabapentin,
900–1,200 mg/day; topiramate, 100 mg/day; levetirac-
etam, 1,500 mg/day; and lamotrigine, 100 mg/day.
Conclusions
On the basis of their action on key-mechanisms, valproic
acid, gabapentin, topiramate, levetiracetam and lamotrig-
ine have all the requisites in terms of efficacy, tolerability
and rapid onset of action to be considered first-choice
drugs rather than simply an alternative to the drugs cur-
rently used.
However, with the current availability of antiepileptic
drugs for the prophylaxis of headache, particular attention
should be paid to the correct indications for their use and also
to their side-effects that can invalidate therapeutic results.
Although these adverse effects are often correlated to
the dosage, important side effects may also occur at the
dosages recommended for headache prophylaxis.
Furthermore, the widening of medical areas in which
antiepileptic drugs are prescribed and the growing number
of patients using them requires an increased sensitization
in order to avoid their incorrect use.
Lastly, it should be underlined that the non-homoge-
neous therapeutic schemes found in the literature suggest
the need of adopting algorithms so as to avoid empiric
treatments, in order to permit comparisons and to confirm
the efficacy of therapeutic regimes that are suggested by
preliminary studies. Their manageability and rapid onset
of action should also be verified.
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